Despite receiving CHMP approval earlier this month, Pfizer has announced it does not currently plan to launch Amsparity (adalimumab) in the EU, citing unfavourable market conditions.
Home / Search Results
Stay informed about important legal and industry news with our blogs and weekly BioBlast® updates.
By Naomi Pearce | Feb 28, 2020
Despite receiving CHMP approval earlier this month, Pfizer has announced it does not currently plan to launch Amsparity (adalimumab) in the EU, citing unfavourable market conditions.
By Naomi Pearce | Feb 28, 2020
On 28 February 2020, Harbour BioMed announced FDA approval of its Investigational New Drug application for HBM4003, an anti-CTLA-4 antibody and candidate for the treatment of advanced solid tumours.
By Naomi Pearce | Feb 27, 2020
As we previously foreshadowed, the innovation patent system has been given its end dates:
25 August 2021: last date to lodge innovation patents; and
25 August 2029: da...
By Bioblast Editor | Feb 26, 2020
Sandoz’s US President announced a focus on biosimilars and complex generics as it re-prioritises its US portfolio. As part of the re-prioritisation, Sandoz will sell much of its small molecule generics portfolio to Aurobindo Pharma.
By Bioblast Editor | Feb 24, 2020
On 24 Feb 2020, Canadian News Agency Folio drew attention to a study released by the University of Alberta revealing doctors may face legal and ethical challenges when switching patients to biosimilars. The study suggests that despite a body of evidence supporting the safet...
By Bioblast Editor | Feb 24, 2020
On 24 Feb 2020, the FDA launched a searchable version of the ‘Purple Book’, containing information about FDA licensed biological products.
By Naomi Pearce | Feb 24, 2020
Significant biosimilar activities this week include
12 Feb 20 | Wockhardt announced divestment of assets to Dr Reddy’s, under which 62 products and a manufacturing facility will be sold for $259 million. Wockhardt stated that the funds will enable it to invest i...
By Bioblast Editor | Feb 18, 2020
AbbVie outlines defence strategy for Humira® (adalimumab) competition in the US market. CEO Gonzalez stated that AbbVie’s strategy will be based on the strategy already employed in Europe and other markets, while also admitting that global competition was much more ag...
By Naomi Pearce | Feb 18, 2020
On 18 Feb 2020, BioPharma Reporter reported that AbbVie had outlined its defence strategy for Humira (adalimumab) competition in the US market. According to the BioPharma Reporter, AbbVIe CEO Gonzalez that explained AbbVie’s commercial US strategy will mimic the strat...
By Bioblast Editor | Feb 13, 2020
Despite receiving CHMP approval earlier this month, Pfizer has announced it does not currently plan to launch Amsparity® (adalimumab) in the EU, citing unfavourable market conditions.
SUBSCRIBE TO PEARCE IP